Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMpassion131: Atezolizumab plus paclitaxel vs placebo plus paclitaxel in untreated advanced triple-negative breast cancer
jRCT2080223759Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Atezolizumab + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival (PFS). Started Dec 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080223759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223759.